Download PDF
Digestive Disease Interventions 2024; 08(04): 251-255
DOI: 10.1055/s-0044-1788556
Review Article

Overcoming Boundaries: Interventional Oncology Paving the Way for Cholangiocarcinoma Resection

Yilun Koethe 
1   Department of Interventional Radiology, TRG Medical Imaging, Portland, Oregon
,
Varshana Gurusamy
2   Division of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Intrahepatic cholangiocarcinoma (ICC) has been increasing in the United States and other Western countries and carries a very poor prognosis. Currently, the only curative option is surgical resection, which can increase the 5-year survival from 5 to 30%. However, only 15% of cases of ICC are resectable at the time of diagnosis. With the development of new interventional treatment strategies, including radioembolization, chemoembolization, and portal and hepatic venous embolization, interventional radiologists are playing an increasing role in downstaging and improving the survival outcomes of patients who were initially unresectable.

Keywords

cholangiocarcinoma - interventional oncology - downstaging


Publication History

Received: 15 February 2024

Accepted: 24 June 2024

Article published online:
11 November 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Schartz DA, Porter M, Schartz E. et al. Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol 2022; 33 (06) 679-686
    CrossrefPubMedSearch in Google Scholar
  • 2 Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma. OncoTargets Ther 2019; 12: 4489-4498
    CrossrefPubMedSearch in Google Scholar
  • 3 Edeline J, Touchefeu Y, Guiu B. et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020; 6 (01) 51-59
    CrossrefPubMedSearch in Google Scholar
  • 4 Edeline J, Du FL, Rayar M. et al. Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma. Clin Nucl Med 2015; 40 (11) 851-855
    CrossrefPubMedSearch in Google Scholar
  • 5 Bourien H, Palard X, Rolland Y. et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. Eur J Nucl Med Mol Imaging 2019; 46 (03) 669-676
    CrossrefPubMedSearch in Google Scholar
  • 6 Paz-Fumagalli R, Core J, Padula C. et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget 2021; 12 (20) 2075-2088
    CrossrefPubMedSearch in Google Scholar
  • 7 Sarwar A, Ali A, Ljuboja D. et al. Neoadjuvant yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2021; 32 (11) 1560-1568
    CrossrefPubMedSearch in Google Scholar
  • 8 Gupta AN, Gordon AC, Gabr A. et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol 2022; 45 (08) 1117-1128
    CrossrefPubMedSearch in Google Scholar
  • 9 Yu Q, Ungchusri E, Pillai A. et al. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol 2024; 34 (04) 2374-2383
    CrossrefPubMedSearch in Google Scholar
  • 10 Ahmed O, Yu Q, Patel M. et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2023; 34 (04) 702-709
    CrossrefPubMedSearch in Google Scholar
  • 11 Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014; 149 (06) 565-574
    CrossrefPubMedSearch in Google Scholar
  • 12 Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol 2014; 5 (06) E88-E95
    PubMedSearch in Google Scholar
  • 13 Gabr A, Riaz A, Johnson GE. et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging 2021; 48 (02) 580-583
    CrossrefPubMedSearch in Google Scholar
  • 14 Yu Q, Patel M, Kwak D. et al. Segmental yttrium-90 radioembolization using glass microspheres greater than 400 gray for the treatment of intrahepatic cholangiocarcinoma: a preliminary experience. J Vasc Interv Radiol 2023; 34 (11) 1970-1976.e1
    CrossrefPubMedSearch in Google Scholar
  • 15 Young S, Torkian P, Flanagan S, D'Souza D, Sanghvi T, Golzarian J. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization. J Gastrointest Oncol 2023; 14 (05) 2202-2211
    CrossrefPubMedSearch in Google Scholar
  • 16 Kis B, Shridhar R, Mhaskar R. et al. Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-a prospective feasibility study. J Vasc Interv Radiol 2023; 34 (09) 1547-1555
    CrossrefPubMedSearch in Google Scholar
  • 17 Chan SL, Chotipanich C, Choo SP. et al. Selective internal radiation therapy with yttrium-90 resin microspheres followed by gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma: a phase 2 single-arm multicenter clinical trial. Liver Cancer 2022; 11 (05) 451-459
    CrossrefPubMedSearch in Google Scholar
  • 18 Buettner S, Braat AJAT, Margonis GA. et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J Vasc Interv Radiol 2020; 31 (07) 1035-1043.e2
    CrossrefPubMedSearch in Google Scholar
  • 19 Bargellini I, Mosconi C, Pizzi G. et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol 2020; 43 (09) 1305-1314
    CrossrefPubMedSearch in Google Scholar
  • 20 Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17 (02) 484-491
    CrossrefPubMedSearch in Google Scholar
  • 21 Valle J, Wasan H, Palmer DH. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedSearch in Google Scholar
  • 22 Oh DY, Ruth HA, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) EVIDoa2200015.
    CrossrefPubMedSearch in Google Scholar
  • 23 Kelley RK, Ueno M, Yoo C. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023; 401 (10391): 1853-1865
    CrossrefPubMedSearch in Google Scholar
  • 24 Bisello S, Camilletti AC, Bertini F. et al. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. Mol Clin Oncol 2021; 15 (02) 1-8
    CrossrefPubMedSearch in Google Scholar
  • 25 Hawkins MA, Valle JW, Wasan HS. et al. Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial. J Clin Oncol 2024; 42 (16_suppl): 4006-4006
    CrossrefPubMedSearch in Google Scholar
  • 26 Guiu B. Portal vein embolization versus Yttrium-90 radioembolization: the race is not always to the swift...the dosimetry-driven tortoise might well win the day!. J Vasc Interv Radiol 2021; 32 (06) 843-844
    CrossrefPubMedSearch in Google Scholar
  • 27 Burger I, Hong K, Schulick R. et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16 (03) 353-361
    CrossrefPubMedSearch in Google Scholar
  • 28 Aliberti C, Carandina R, Sarti D. et al. Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma. Anticancer Res 2017; 37 (04) 1859-1863
    CrossrefPubMedSearch in Google Scholar
  • 29 Schiffman SC, Metzger T, Dubel G. et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol 2011; 18 (02) 431-438
    CrossrefPubMedSearch in Google Scholar
  • 30 Nevermann N, Bode J, Vischer M. et al. Perioperative outcome and long-term survival for intrahepatic cholangiocarcinoma after portal vein embolization and subsequent resection: A propensity-matched study. Eur J Surg Oncol 2023; 49 (12) 107100
    CrossrefPubMedSearch in Google Scholar
  • 31 Heil J, Korenblik R, Heid F. et al. Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis. Br J Surg 2021; 108 (07) 834-842
    CrossrefPubMedSearch in Google Scholar
  • 32 Marino R, Ratti F, Della Corte A. et al. Comparing liver venous deprivation and portal vein embolization for perihilar cholangiocarcinoma: Is it time to shift the focus to hepatic functional reserve rather than hypertrophy?. Cancers (Basel) 2023; 15 (17) 4363
    CrossrefPubMedSearch in Google Scholar